Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models

Despite significant improvements in procedural technique and stent technology, intravascular stent thrombosis occurs with devastating end-organ consequences, such as limb loss. The findings of this study demonstrate that a targeted, nanomedicine-based, antithrombin approach results in decreased clotting of ex vivo stents, decreased clotting of intravascular stents in flow loops, and improved endothelial cell proliferation. Ultimately, this strategy may provide physicians with a treatment to decrease intravascular stent thrombosis and maintain endothelial cell viability without the systemic bleeding risks associated with dual antiplatelet therapy and systemic anticoagulation.